Fabry disease, an overview and the most common neurological manifestations

Česká verzia

Authors: P. Reková ¹; K. Sedláková ²; G. Dostálová ³; A. Linhart ³
Authors place of work: Neurologická klinika a Centrum klinických neurověd 1. LF UK a VFN v Praze ¹; Oční klinika 1. LF UK a VFN v Praze ²; II. interní klinika – klinika kardiologie a angiologie 1. LF UK a VFN v Praze ³
Published in the journal: Cesk Slov Neurol N 2018; 81(2): 156-163
Category: Review Article
doi: https://doi.org/10.14735/amcsnn2018156

Snímky z MR jsou publikovány se svolením Radiologické kliniky 1. LF UK a VFN, za jejich poskytnutí autoři děkují. Za poskytnutí fotografie kožních angiokeratomů patří poděkování MU Dr. Lukáši Lacinovi, Ph.D., z Dermatovenerologické kliniky 1. LF UK a VFN

Summary

Fabry disease is a rare inherited lysosomal storage disorder. Patients with classical multisystemic disease have frequent neurological manifestations. It is of great importance for patients to be diagnosed early and properly since there is specific disease therapy available. This article provides an overview of current knowledge about Fabry disease with emphasis on its neurological manifestations.

Key words:
Fabry disease – small fi ber neuropathy – stroke – enzyme-replacement therapy

P. Reková has been in receipt of travel grant and honoraria for lectures on Fabry disease from Shire HGT and Sanofi Genzyme. K. Sedláková has been in receipt of honoraria for lectures on Fabry disease from Shire HGT. G. Dostálová has been in receipt of travel grants and honoraria for lecures on Fabry disease from Protalix Biotherapeutics, Shire HGT and Sanofi Genzyme. A. Linhart has been in receipt of travel grants and honoraria for lectures on Fabry disease from Shire HGT, Sanofi Genzyme and Amicus Therapeutics.

The Editorial Board declares that the manuscript met the ICMJE “uniform requirements” for biomedical papers.

Zdroje

1. Germain DP. Fabry disease. Orphanet J Rare Dis 2010; 5: 30. doi: 10.1186/ 1750-1172-5-30.

2. Anderson W. A case of angiokeratoma. BR J Dermatol 1898; 10: 113– 117.

3. Fabry J. Ein Beitrag zur Kenntnis der Purpura hae-morhagica nodularis (Purpura papulosa haemorrhagica herbae). Arch Derm Syph 1898; 43: 187– 200.

4. Sweeley CC, Klionsky B. Fabry‘s disease: classification as a sphingolipidosis and partial characterization of a novel glycolipid. J Biol Chem 1963; 238: 3148– 3150.

5. Brady RO, Gal AE, Bradley RM et al. Enzymatic defect in Fabry‘s disease. Ceramidetrihexosidase deficiency. N Engl J Med 1967; 276(21): 1163– 1167. doi: 10.1056/ NEJM196705252762101.

6. Kornreich R, Desnick REJ, Bishop DF. Nucleotide sequence of the human alpha-galactosidase A gene. Nucleic Acids Res 1989; 17(8): 3301– 3302. doi: 10.1093/ nar/ 17.8.3301.

7. Ohshima T, Murray GJ, Nagle JW et al. Structural organization and expression of the mouse gene encoding alpha-galactosidase. Gene 1995; 166(2): 277– 280. doi: 10.1016/ 0378-1119(95)00592-7.

8. Meikle PJ, Hopwood JJ, Clauge AE et al. Prevalence of lysosomal storage disorders. JAMA 1999; 281(3): 249– 254. doi: 10.1001/ jama.281.3.249.

9. Spada M, Pagliardini S, Yasuda M et al. High incidence of later-onset Fabry disease revealed by newborn screening. Am J Hum Genet 2006; 79(1): 31– 40. doi: 10.1086/ 504601.

10. Lin HY, Chong KW, Hsu HJ et al. High incidence of the cardiac variant of fabry disease revealed by newborn screening in the taiwan Chinese population. Circ Cardiovasc Genet 2009; 2(5): 450– 456. doi: 10.1161/ CIRCGENETICS.109.862920.

11. Linthorst GE, Bouwman MG, Wijburg FA et al. Screening for Fabry disease in high-risk populations: a systematic review. J Med Genet 2010; 47(4): 217– 222. doi: 10.1136/ jmg.2009.072116.

12. Rolfs A, Bottcher T, Zschiesche M et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet 2005; 366(9499): 1794– 1796. doi: 10.1016/ S0140-6736(05)67635-0.

13. Brouns R, Thijs V, Eyskens F et al. Belgian Fabrystudy: prevalence of Fabry disease in a cohort of 1000 young patients with cerebrovascular disease. Stroke 2010; 41(5): 863– 868. doi: 10.1161/ STROKEAHA.110.579409.

14. Shi Q, Chen J, Pongmoragot J et al. Prevalence of Fabry disease in stroke pacients – a systematic review and meta-analysis. J Stroke Cerebrobvasc Dis 2014; 23(5): 985– 992. doi: 10.1016/ j.jstrokecerebrovasdis.2013.08.010.

15. Český statistický úřad: Obyvatelstvo. Česká republika 2017. Dostupné z URL: https: / / www.czso.cz/ csu/ czso/ obyvatelstvo_lide.

16. Merta M, Reiterová J, Ledvinová J et al. A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population. Nephrol Dial Transplant 2007; 22(1): 179– 186. doi: 10.1093/ ndt/ gfl528.

17. Paleček T, Honzíková J, Poupětová H et al. Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: prospective Fabry cardiomyopathy screening study (FACSS). J Inherit Metab Dis 2014; 37(3): 455– 460. doi: 10.1007/ s10545-013-9659-2.

18. Ross MT, Grafham DV, Coffey AJ et al. The DNA sequence of the human X chromozome. Nature 2005; 434(7031): 325– 337. doi: 10.1038/ nature03440.

19. National Center for Biotechnology Information. ClinVar. Bethesda, USA: National Library of Medicine 2018. Dostupné z URL: https:/ / www.ncbi.nlm.nih.gov/ clinvar/ .

20. Aerts JM, Groener JE, Kuiper S et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A 2008; 105(8): 2812– 2817. doi: 10.1073/ pnas.0712309105.

21. Lidove O, Ramaswai U, Jaussaud R et al. Hyperhidrosis: a new and often early symptom in Fabry disease. International experience and data from the Fabry Outcome Survey. Int J Clin Pract 2006; 60(9): 1053– 1059. doi: 10.1111/ j.1742-1241.2006.01061.x

22. Kalkum G, Pitz S, Karabul N et al. Paediatric Fabry disease: prognostic significance of ocular changes for disease severity. BMC Ophthalmol 2016; 16(1): 202. doi: 10.1186/ s12886-016-0374-2.

23. Sims K, Politei J, Banikazemi M et al. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke 2009; 40(3): 788– 794. doi: 10.1161/ STROKEAHA.108.526293.

24. Dobrovolný R, Dvořáková L, Ledvinová J et al. Relationship between X-inactivatin and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population. J Mol Med (Berl) 2005; 83(8): 647– 654. doi: 10.1007/ s00109-005-0656-2.

25. Kolodny EH, Pastores GM. Anderson – Fabry disease: extrarenal, neurologic manifestations. J Am Soc Nephrol 2002; 13 (Suppl 2): S150– S153. doi: 10.1097/ 01.ASN.0000015239.57436.18.

26. Kahn P. Anderson – Fabry disease: a histopathological study of three cases with observations on the mechanism of production of pain. J Neurol Neurosurg Psychiatry 1973; 36: 1053– 1062.

27. Politei JM, Bouhassira D, Germain DP et al. Pain in Fabry disease: practical recommendations for diagnosis and treatment. CNS Neurosci Ther 2016; 22(7): 568– 576. doi: 10.1111/ cns.12542.

28. Hoffmann B, Beck M, Sunder-Plassmann G et al. Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy – a retrospective analysis from the Fabry Outcome Survey. Clin J Pain 2007; 23(6): 535– 542. doi: 10.1097/ AJP.0b013e318074c986.

29. Mehta A, Ricci R, Widmer U et al. Fabry disease defined: baseline clinical manifestation of 48366 patients in the Fabry Outcome Survey. Eur J Clin Invest 2004; 34(3): 236– 242. doi: 10.1111/ j.1365-2362.2004.01309.x.

30. Ginsberg L. Nervous system manifestations of Fabry disease: data from FOS – the Fabry Outcome Survey. In: Mentha A, Beck M, Sunder-Plassmann G (eds). Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis 2006: 227– 232.

31. Miners AH, Holmes A, Sherr L et al. Assessment of health-related quality of life in males with Anderson Fabry Disease before therapeutic intervention. Qual Life Res 2002; 11(2): 127– 133. doi: 10.1023/ A: 1015009210639.

32. Baehner F, Kampmann C, Whybra C et al. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study. J Inherit Metab Cis 2003; 26(7): 617– 627. doi: 10.1023/ B: BOLI.0000005658.14563.77.

33. Cable WJ, Kolodny EH, Adams RD. Fabry disease: impaired autonomic function. Neurology 1982; 32(5): 498– 502. doi: 10.1212/ WNL.32.5.498.

34. Mutoh T, Senda Y, Sugimura K. Severe orthostatic hypotension in Female a carrier of Fabry disease. Arch Neurol 1988; 45(4): 468– 472. doi: 10.1001/ archneur.1988.00520280122030.

35. O‘Mahony C, Coats C, Cardona M et al. Incidence and predictors of anti-bradycardia pacing in patients with Anderson-Fabry disease. Europace 2011; 13(12): 1781– 1788. doi: 10.1093/ europace/ eur267.

36. Hilz MJ, Kolodny EH, Brys M et al. Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. J Neurol 2004; 251(5): 564– 570. doi: 10.1007/ s00415-004-0364-9.

37. Kaye EM, Kolodny EH, Logigian EL et al. Nervous system involvement in Fabry’s disease: clinicopathological and biochemical correlation. Ann Neurol 1988; 23(5): 505– 509. doi: 10.1002/ ana.410230513.

38. Moore DF, Kaneski CR, Askari H et al. The cerebral vasculopathy of Fabry disease. J Neurol Sci 2007; 257(1– 2): 258– 263. doi: 10.1016/ j.jns.2007.01.053.

39. Elleder M, Chrostomanou H, Kustermann-Kuhn B et al. Leptomeningeal lipid storage patterns in Fabry disease. Acta Neuropathol 1994; 88(6): 579– 582. doi: 10.1007/ BF00296496.

40. Gupta S, Ries M, Kotsopoulos S et al. The relationship of vascular glycolipid storage to clinical manifestations of Fabry disease: a cross-sectional study of a large cohort of clinically affected heterozygous woman. Medicine (Baltimore) 2005; 84(5): 261– 268. doi: 10.1097/ 01.md.0000178976.62537.6b.

41. Vedder AC, Linthorst GE, Van Breemen MJ et al. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J Inherit Metab Dis 2006; 30(1): 68– 78. doi: 10.1007/ s10545-006-0484-8.

42. Fellgiebel A, Keller I, Martus P et al. Basilar artery diameter is a potential screening tool for Fabry disease in young stroke patients. Cerebrovasc Dis 2011; 31(3): 294– 299. doi: 10.1159/ 000322558.

43. Carbera-Salazar MA, O‘Rourke E, Charia-Ortiz G et al. Radiological evidence of early cerebral microvascular disease in young children with Fabry disease. J Paediatr 2005; 147(1): 102– 105. doi: 10.1016/ j.jpeds.2005.03.004.

44. Rost NS, Cloonan L, Kanakis AS et al. Determinants of white matter hyperintensity burden in patients with Fabry disease. Neurology 2016; 86(20): 1880– 1886. doi: 10.1212/ WNL.0000000000002673.

45. Cocozza S, Olivo G, Riccio E et al. Corpus callosum involvement: a useful clue for differentiating Fabry disease from multiple sclerosis. Neuroradiology 2017; 59(6): 563– 570. doi: 10.1007/ s00234-017-1829-8.

46. Moore DF, Ye F, Schiffmann R et al. Increased signal intensity in the pulvinar on T1-wighted images: A pathognomonic MR imaging sign of Fabry disease. AJNR Am J Neuroradiol 2003; 24(6): 1096– 1101.

47. Gavazzi C, Borsini W, Guerrini L et al. Subcortical damage and cortical functional changes in men and women with Fabry disease: a multifaceted MR study. Radiology 2006; 241(2): 492– 500. doi: 10.1148/ radiool.2412051122.

48. Cocozza S, Russo C, A. Pisani et al. Redefining the pulvinar sign in Fabry disease. AJNR Am J Neuroradiol 2017; 38(12): 2264– 2269. doi: 10.3174/ ajnr.A5420.

49. Linhart A, Elliott PM. The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart, 2007; 93(4): 528– 535. doi: 10.1136/ hrt.2005.063818

50. Pitz S, Kalkum G, Arash L et al. Ocular signs correlate well with disease severity and genotype in Fabry disease. PloS One 2015; 10(3): e0120814. doi: 10.1371/ journal.pone.0120814.

51. Sodi A, Ioannidis A, Pitz S. Ophthalmological manifestations of Fabry disease. In: Mehta A, Beck M, Sunder-Plassmann G (eds). Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis 2006.

52. Raizman MB, Hamrah P, Holland EJ et al. Drug-induced corneal epithelial changes. Surv Ophthalmol 2017; 62(3): 286– 301. doi: 10.1016/ j.survophthal.2016.11.008.

53. Keilmann A, Hegemann S, Conti G et al. Fabry disease and the ear. In: Mehta A, Beck M, Sunder-Plassmann G (eds). Fabry disease: perspectives from 5 years of FOS. Oxford: Oxford PharmaGenesis 2006: 227-232.

54. Laney DA., Fernhoff PM. J Diagnosis of Fabry disease via analysis of family history. J Genet Couns 2008; 17(1): 79-83. doi: 10.1007/ s10897-007-9128-x.

55. Eng CM, Guffon N, Wilcox WR et al. Safety and efficacy of recombinant human alpha-galactosidase A – replacement therapy in Fabry’s disease. N Engl J Med 2001; 345(1): 9– 16. doi: 10.1056/ NEJM200107053450102.

56. Thurberg BL, Byers HR, Granter SR et al. Monitoring the 3-year efficacy of enzyme replacement therapy in Fabry disease by repeated skin biopsies. J Invest Dermatol 2004; 122(4): 900– 908. doi: 10.1111/ j.0022-202X.2004. 22425.x.

57. Banikazemi M, Bultas J, Waldek S et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 2007; 146(2): 77– 86. doi: 10.7326/ 0003-4819-146-2-200701160-00148.

58. Schiffmann R, Kopp JB, Austin HA 3rd et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001; 285(21): 2743– 2749. doi: 10.1001/ jama.285.21.2743.

59. Ortiz A, Abiose A, Bichet DG et al. Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry. J Med Genet 2016; 53(7): 495– 502. doi: 10.1136/ jmedgenet-2015-103486.

60. Goláň L. Migalastat v terapii Fabryho choroby. Interní Med 2017; 19(3). 167– 170.

61. Guérard N, Oder D, Nordbeck P et al. Lucerastat, an iminosugar for substrate reduction therapy: tolerability, pharmacodynamics, and pharmacokinetics in patients with Fabry Disease on enzyme replacement. Clin Pharmacol Ther 2018; 103(4): 703– 711. doi: 10.1002/ cpt.790.

62. Huang J, Khan A, Au BC et al. Lentivector iterations and pre-clinical scale-up/ toxicity testing: targeting mobilized cd34+ cells for correction of Fabry disease. Mol Ther Methods Clin Dev 2017; 5: 241– 258. doi: 10.1016/ j.omtm.2017.05.003.

63. Biegstraaten M, Arngrímsson R, Barbey F et al. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphane J Rare Dis 2015; 10: 36. doi: 10.1186/ s13023-015-0253-6.